Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.685
Sell
RSI(14)
38.059
Neutral
STOCH(KDJ)(9,3,3)
27.059
Buy
ATR(14)
1.593
High Vlolatility
CCI(14)
-63.898
Neutral
Williams %R
69.321
Sell
TRIX(12,20)
-0.778
Sell
StochRSI(14)
100.000
Buy
Search
STAAR Surgical Co
STAAAdd to Watchlist
24.280USD
+0.410+1.72%
Close 07-29 16:00（ET）Quotes delayed by 15 min
1.20BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+1.72%
5 Days
-1.74%
1 Month
-17.22%
6 Months
+28.19%
Year to Date
+5.15%
1 Year
+30.68%
Key Figures
22.540Open
24.370High
1.00Volume
LossP/E TTM
48.15P/E Dynamic
--Dividend TTM
0.00%Turnover Ratio
23.870Prev. Close
22.500Low
24.00Turnover
LossP/E Static
3.49P/B
0.00%Div Yield TTM
-4.63%ROA
30.81052wk High
-0.00Volume Ratio
-20.21MNet Profit
49.40MShares
-0.4200EPS TTM
1.02Beta
-5.99%ROE
14.69052wk Low
7.83%Amplitude
73.63%Gross Margin
1.20BMarket Cap
-5.40Reward/Risk
3.11%Risk Rate
TradingKey Stock Score of STAAR Surgical Co
Currency: USD Updated: 2026-07-29Key Insights
STAAR Surgical Co's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 35 out of 199 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 29.67.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
STAAR Surgical Co's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
STAAR Surgical Co Highlights
StrengthsRisks
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Undervalued
The company’s latest PE is -56.83, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 58.06M shares, decreasing 15.41% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 31.04K shares of this stock.
Analyst Rating
Based on
11
analysts
Hold
Current Rating
29.667
Target Price
+29.27%
Upside Space
Earnings Forecast
Analyst Rating
Based on
11
analysts
Hold
Current Rating
29.667
Target Price
+29.27%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
109
Total
7
Median
9
Average
Company name
Ratings
Analysts
STAAR Surgical Co
STAA
11
Medtronic PLC
MDT
34
Dexcom Inc
DXCM
32
Zimmer Biomet Holdings Inc
ZBH
31
Stryker Corp
SYK
31
Abbott Laboratories
ABT
31
1
2
3
...
22
Indicators
Moving Average
Indicators
Value
Direction
MA5
23.410
Buy
MA10
24.542
Sell
MA20
26.137
Sell
MA50
28.450
Sell
MA100
25.751
Sell
MA200
24.362
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
STAAR Surgical Co Info
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Ticker SymbolSTAA
CompanySTAAR Surgical Co
CEOFarrell (Stephen C)
Websitehttps://www.staar.com/
Shareholders
Related Instruments
-0.69%
-0.83%
-1.59%
0.00%
0.00%
-0.64%
-0.88%
-0.55%
-0.17%
+2.05%
-3.95%
-0.11%
0.00%
+2.51%
0.00%
0.00%
-0.76%
0.00%
-0.36%
-0.32%Popular Instruments
51801.700
+243.700 (+0.47%)
27663.900
+550.100 (+2.03%)
7366.900
+64.100 (+0.88%)
14696.000
+10.000 (+0.07%)
62725.000
+1796.000 (+2.95%)
6311.700
+91.200 (+1.47%)
83.440
-0.501 (-0.60%)
336.490
-1.700 (-0.50%)
193.400
+3.390 (+1.78%)
4071.800
+4.660 (+0.12%)
FAQs
What is the current price of STAAR Surgical Co (STAA)?
The current price of STAAR Surgical Co (STAA) is 23.87.
What is the symbol of STAAR Surgical Co?
The ticker symbol of STAAR Surgical Co is STAA.
What is the 52-week high of STAAR Surgical Co?
The 52-week high of STAAR Surgical Co is 30.81.
What is the 52-week low of STAAR Surgical Co?
The 52-week low of STAAR Surgical Co is 14.69.
What is the market capitalization of STAAR Surgical Co?
The market capitalization of STAAR Surgical Co is 1.18B.
Is STAAR Surgical Co (STAA) currently rated as Buy, Hold, or Sell?
According to analysts, STAAR Surgical Co (STAA) has an overall rating of signal_hold, with a price target of 29.67.
What is the Earnings Per Share (EPS TTM) of STAAR Surgical Co (STAA)?
The Earnings Per Share (EPS TTM) of STAAR Surgical Co (STAA) is -1.62.